^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor +
    Aromatase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer

    Published date:
    07/29/2021
    Excerpt:
    A nonsteroidal aromatase inhibitor (AI) and a CDK4/6 inhibitor should be offered to postmenopausal women with treatment-naive HR-positive MBC.
    DOI:
    10.1200/JCO.21.01392